Bicycle Therapeutics PLC represents values of innovation, collaboration, and patient-centricity. As a biotechnology company, Bicycle Therapeutics focuses on developing novel therapeutics using its proprietary Bicycle Drug Conjugate (BDC) platform. The company aims to address unmet medical needs and improve patient outcomes through the targeted delivery of drugs. Bicycle Therapeutics emphasizes scientific excellence, fostering partnerships, and translating scientific discoveries into potential therapies. By leveraging its unique technology, the company strives to develop drugs with enhanced efficacy and reduced side effects. Bicycle Therapeutics PLC is committed to advancing therapeutics that have the potential to transform the lives of patients and contribute to the advancement of medical science.

Bicycle Therapeutics PLC primarily operates in the United Kingdom and the United States. The company is based in Cambridge, UK, and its main focus is on developing a new class of medicines using its unique bicyclic peptide (Bicycle®) technology. With its presence in the UK and the US, Bicycle Therapeutics PLC remains dedicated to advancing its innovative therapeutic platform and collaborating with various partners to enhance the treatment options for patients globally.

Bicycle Therapeutics PLC has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in May 2019, raising substantial funds to support its ongoing research and development efforts. Bicycle Therapeutics also entered into several strategic collaborations and partnerships, including a collaboration with AstraZeneca in 2016 to develop bicycle-based therapeutics in oncology and an agreement with Bioverativ in 2018 for the discovery and development of novel therapies for hemophilia and sickle cell disease. These partnerships have further strengthened the company's position in the biotechnology industry. Additionally, Bicycle Therapeutics achieved regulatory milestones with the initiation of clinical trials for its drug candidates, demonstrating progress towards potential commercialization.

Bicycle Therapeutics PLC is a leading clinical-stage biopharmaceutical company specializing in the development of bicyclic peptides. Founded in 2009 in Cambridge, England, Bicycle Therapeutics has emerged as a pioneer in the field of peptide-based therapeutics. The company's proprietary technology allows for the precise targeting of disease-related proteins, offering a potential breakthrough in the treatment of various diseases, including cancer. Bicycle Therapeutics has established strategic partnerships with renowned pharmaceutical companies, further validating its innovative approach. With a strong commitment to research and development, the company continues to advance its pipeline and explore new applications for its unique technology platform.

The main competitors of Bicycle Therapeutics PLC in the market include large pharmaceutical companies specializing in the development of oncology drugs, such as Roche Holding AG, Novartis AG, and AstraZeneca plc. These companies compete with Bicycle Therapeutics in the field of targeted therapy using innovative bicyclic peptides. Additionally, other biotechnology companies focusing on cancer therapeutics, such as Amgen Inc., Celgene Corporation, and Gilead Sciences Inc., pose competition in the market. Bicycle Therapeutics PLC differentiates itself through its proprietary bicyclic peptide platform and strategic collaborations with industry leaders.

Bicycle Therapeutics PLC is primarily active in the biotechnology and pharmaceutical industries. As a leading company in the field, Bicycle Therapeutics PLC focuses on developing innovative therapeutics based on its proprietary bicyclic peptide platform. Through its extensive research and development efforts, the company aims to address unmet medical needs in various therapeutic areas, including oncology and respiratory diseases. With its cutting-edge technology and strategic collaborations, Bicycle Therapeutics PLC is committed to advancing the next generation of targeted therapies to improve patient outcomes and revolutionize the treatment landscape.

Bicycle Therapeutics PLC is a biotechnology company specializing in the development of novel therapeutics using its proprietary bicyclic peptide (Bicycle) platform. The company's business model focuses on discovering and developing highly selective and potent Bicycle-based drugs to target diseases with high unmet medical needs. Bicycle Therapeutics leverages its unique platform to create precise and targeted therapies that have the potential to address a wide range of diseases, including oncology and inflammatory conditions. By combining the benefits of large molecules with the properties of small molecules, Bicycle Therapeutics aims to deliver innovative and effective treatments for patients worldwide.

Bicycle Therapeutics의 P/E 비율은 -3.22입니다.

Bicycle Therapeutics의 P/S 비율은 18.34입니다.

Bicycle Therapeutics에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 Bicycle Therapeutics 매출은 39.22 백만 USD입니다.

예상되는 Bicycle Therapeutics 이익은 -223.65 백만 USD입니다.

Bicycle Therapeutics is a biotech company that focuses on the development of drugs based on bicycle technology. This innovative method allows for more targeted and effective modification of proteins compared to conventional methods. The company's business model revolves around the development and marketing of bicycle-based drugs in various medical fields. They specialize in oncology, developing drugs that selectively attack and destroy cancer cells. They also work in immunology to influence and support the immune system, such as combating autoimmune diseases or assisting in cancer immunotherapy. Additionally, Bicycle Therapeutics develops drugs for various indications, including neurology, infectious diseases, and cardiology. Collaborations with pharmaceutical and biotech companies are a crucial part of Bicycle Therapeutics' business model. Overall, the company offers a wide range of products using their innovative bicycle technology and aims to bring effective and targeted drugs to market through partnerships.

Bicycle Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Bicycle Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Bicycle Therapeutics의 ISIN은 US0887861088입니다.

Bicycle Therapeutics의 WKN은 A2PKZC입니다.

Bicycle Therapeutics의 티커는 BCYC입니다.

지난 12개월 동안 Bicycle Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Bicycle Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Bicycle Therapeutics의 현재 배당 수익률은 입니다.

Bicycle Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Bicycle Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Bicycle Therapeutics은 '건강' 섹터에 속합니다.

Bicycle Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Bicycle Therapeutics는 0 USD를 배당금으로 지급했습니다.

Bicycle Therapeutics의 배당금은 USD에 지급됩니다.